Eli Lilly shares rise 1.32% premarket after positive Phase 3 trial results for obesity pill.

Eli Lilly And Company rose 1.32% in premarket trading, driven by positive news from the Phase 3 ATTAIN-2 trial of its investigational oral GLP-1 receptor agonist, orforglipron. The trial showed significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors at 72 weeks, with participants losing an average of 22.9 pounds. This positive development has boosted investor confidence in the company's obesity treatment pipeline.